MetaVia Advances Cardiometabolic Disease Treatments with Promising Drug Candidates and Upcoming Investor Forum

MetaVia Inc. (MTVA), a clinical-stage biotechnology company based in Cambridge, Massachusetts, focuses on advancing innovative therapies aimed at combating cardiometabolic diseases.

Innovative Drug Pipeline

The company is actively developing two key drug candidates: DA-1726 and vanoglipel (DA-1241), which target obesity and metabolic dysfunction, respectively. In an upcoming fireside chat at the Life Sciences Virtual Investor Forum on June 24, 2026, President and CEO Hyung Heon Kim will present the company's pipeline, highlighting its commitment to addressing significant health challenges.

This event will offer an interactive platform for investors, with a webcast available for those unable to attend live.

Promising Clinical Trials

Both DA-1726 and vanoglipel show considerable promise in their clinical pathways. DA-1726 is currently in Phase 1 trials, functioning as a dual agonist to enhance weight loss and improve glucose control compared to existing treatments.

Addressing Major Health Challenges

Vanoglipel is in Phase 2a trials and has exhibited benefits in managing Metabolic Dysfunction-Associated Steatohepatitis. MetaVia's work excels in transforming the treatment landscape for obesity and metabolic disorders, affirming its role as a key player in the biotechnology industry dedicated to enhancing patient outcomes.

For further details, interested parties can visit the company’s website at www.metaviatx.com.